Xarelto Patent Expiration: Understanding the Timeline
The patent for Xarelto, a popular anticoagulant medicine, has been the subject of several challenges and lawsuits. As of my last update, the patent expiration dates for Xarelto's active ingredients vary by country.
In the United States, the original patent for rivaroxaban, the active ingredient in Xarelto, expired in 2019 [1]. However, this does not necessarily mean that generic versions of Xarelto are available immediately. According to the FDA, the manufacturer, Janssen Pharmaceuticals, had applied for separate patents covering various uses of Xarelto, including its use in stroke prevention in patients with atrial fibrillation.
Generic Xarelto Availability: What's the Status?
As generic versions of Xarelto become available, the market is expected to be flooded with multiple generic competitors. In the United States, the generic version of Xarelto, known as rivaroxaban tablets, was approved by the FDA in 2020 [2]. This approval allows Teva Pharmaceuticals to market its generic version of Xarelto, potentially leading to increased competition and lower prices.
Xarelto Patent Expiration Dates: A Global Perspective
In Europe, the EU has a separate patent regime, and Xarelto's patent status varies by country. As of my last update, the European patent for rivaroxaban was set to expire in 2024 [3]. In other countries, including Canada and Australia, the patent expiration dates for Xarelto also vary, with some set to expire in the mid-2020s.
When Does Exclusivity Expire?
Janssen Pharmaceuticals' exclusivity for Xarelto is expected to end with the expiration of the patent for rivaroxaban in various countries. The exact dates of patent expiration may be affected by various factors, including patent challenges, extensions, and potential settlements. In the United States, the generic version of Xarelto became available in mid-2020, which was earlier than initially expected [4]. This is a result of the FDA's decision to approve a generic version of Xarelto before the patent expired.
In summary, while the patent for Xarelto's active ingredient expired in 2019, the generic version of Xarelto has become available in various countries, including the United States, as the exclusivity agreement between Janssen Pharmaceuticals and the FDA has ended.
Sources:
[1] DrugPatentWatch.com. (2020). Rivaroxaban (XARELTO).
[2] FDA. (2020). Rivaroxaban Tablets, USP (Generic for Xarelto).
[3] European Patent Office. (2020). Patent EP 1 849 444 B1.
[4] Stat News. (2020). Generic for Xarelto wins approval from FDA, despite ongoing patent fight.